FOLFOX plus bevacizumab alternated with sLV5FU2 plus bevacizumab as first-line chemotherapy for patients with metastatic colorectal cancer: a feasibility study

ABSTRACT: Interventions: Treatment consisted of modified mFOLFOX6 plus bevacizumab alternated biweekly with 5-FU/LV (simplified LV5FU2) plus bevacizumab. Treatment was administered until tumor progression, unacceptable toxicity or patient refusal. Primary outcome(s): Response rate Safety Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2619131 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR